Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present disclosure provides use of a human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (hucMSC-sEV) in preparation of a drug for treating type 2 diabetes mellitus (T2DM), and belongs to the technical field of biomedicine. In the present disclosure, experiments have verified that the hucMSC-SEV can effectively reduce blood glucose in a db/db mouse model, improve a morphological disorder of pancreatic islets, and increase a number of ? cells. Moreover, the hucMSC-sEV can also remodel pancreatic ? cells by reversing apoptosis and dedifferentiation of the ? cells. It is confirmed that the hucMSC-sEV is an effective pharmaceutical ingredient that improves pancreatic islet functions, and can effectively ameliorate T2DM, regulate glucose homeostasis, improve a pancreatic islet structure, and increase a quality of the pancreatic islet ? cells, thereby achieving therapeutic effects from a root cause of the disease.

Abstract: A heat dissipation structure includes a housing. The housing has opposing upper and lower surfaces, and a fluid channel between the upper surface and the lower surface. The fluid channel is configured to allow a fluid to pass through, and the fluid channel includes an inlet buffer tank, an outlet buffer tank and a connecting structure. The inlet buffer tank has opposing first inner wall and second inner wall surfaces. The outlet buffer tank has opposing first inner wall and second inner wall surfaces, and the second inner wall surface is closer to the inlet buffer tank than the first inner wall surface. The connecting structure is disposed on the inlet buffer tank and the outlet buffer tank, in which the connecting structure has a first bevel surface and a second bevel surface connected to the upper surface of the housing.

Abstract: A light directing arrangement (52) is provided for directing output light from a lighting unit (50), comprising an arrangement of panels (10). The panels (10) form a funnel-type structure for limiting beam spreading from a light emitting area of the lighting unit (50). At least one panel (10) has openings in opposite surfaces (14, 22), with direct light paths between the openings blocked but an air flow passage (32) is provided between the openings. In this way, forces experienced in windy conditions are reduced.

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Abstract: A four leg, lower extremity, robotic exoskeleton system is provided for medically assistive motion in gait, sit to stand (STS) and step climbing activities. The system has four articulated robotic legs, including two exoskeleton legs and two auto-pole legs, which are connected to a torso frame, controlled by a motion controller and a user interfaces, and that interacts with an assistive stationary robotic chair, or a wheelchair, for storage, dressing, STS and rest. The STS motion, in the stationary chair and the wheelchair, may be done with a single axis linear actuator, which maintains a back seat tip parallel to the ground for safety and comfort. Links of the exoskeleton and auto-pole legs are actuated by a linear or rotary actuators with their synchronized motion controlled by the motion controller, for safety, comfort and cost performance optimization depending on the medical needs.

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Abstract: Polymers of intrinsic microporosity are used herein as polymer templates for forming mechanical robust inorganic porous coatings that can be beneficially used as anti-reflective coatings.

Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Abstract: A positive electrode plate, a secondary battery, a battery module, a battery pack, and a power consuming device are described. The positive electrode plate include a positive electrode current collector and positive electrode film layers having a single-layer or multi-layer structure.

Abstract: A positive electrode plate may comprise a positive electrode current collector and positive electrode film layers having a single-layer or multi-layer structure provided on at least one surface of the positive electrode current collector; when the positive electrode film layers have a single-layer structure, at least one of the positive electrode film layers may comprise a first positive electrode active material and a second positive electrode active material selected from LiFePO4, carbon-coated LiFePO4, LiFebDcPO4 and carbon-coated LiFebDcPO4; and/or when the positive electrode film layers have a multi-layer structure, at least one layer of the at least one of the positive electrode film layers may comprise the first and second positive electrode active materials; and the first positive electrode active material may comprise an inner core containing Li1+xMn1-yAyP1-zRzO4, a first coating layer containing pyrophosphate and phosphate, and a second coating layer containing a carbon element.

Abstract: A positive electrode plate, a secondary battery, a battery module, a battery pack and a power consuming device are provided. In some embodiments, the positive electrode plate comprises a positive electrode current collector and a positive electrode film layer having a single-layer or multi-layer structure provided on at least surface of the positive electrode current collector; when the positive electrode film layer has a single-layer structure, at least one of the positive electrode film layers contains both a first positive electrode active material with a chemical formula of LiaAxMn1-yRyP1-zCzO4-nDn and a second positive electrode active material selected from LiFePO4, carbon-coated LiFePO4, LiFebMcPO4 and carbon-coated LiFebMcPO4; and/or when the positive electrode film layer has a multi-layer structure, at least one of the positive electrode film layers contains both a first positive electrode active material and a second positive electrode active material.

Abstract: Provided are a programmable device for processing a data set, and a method for processing a data set. The programmable device includes a plurality of accumulation circuits, wherein each of the accumulation circuits includes a pipeline adder and a cache unit for storing a computation result of the pipeline adder; and a multiplexer for receiving in sequence data in a data set, dynamically determining a correlation between a plurality of features included in the data and the plurality of accumulation circuits, and respectively sending, according to the correlation, feature values of the plurality of features in the received data to corresponding accumulation circuits.

Abstract: The present disclosure provides a superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery, and a preparation method thereof, belonging to the technical field of engineered nanovesicle drug loading systems. The superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery prepared by the preparation method acts on tumor cell lines. It is found that the superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery can specifically target tumor cells, induce tumor cell apoptosis, and inhibit tumor growth. The biological preparation significantly extends a survival time of mice and improves an efficacy of drugs against cancers.

Abstract: An electrode assembly, a battery cell, a battery, and a method and device for manufacturing an electrode assembly are provided. In some embodiments, the electrode assembly includes a positive electrode plate and a negative electrode plate. The positive electrode plate and the negative electrode plate are wound or folded to form a bend region. The positive electrode plate includes a plurality of bend portions located in the bend region. Each bend portion includes a positive current collecting layer and a positive active material layer. The positive current collecting layer is coated with the positive active material layer on at least one surface in a thickness direction of the positive electrode plate. A barrier layer is disposed between the positive current collecting layer and the positive active material layer.

Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).